• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卡维地洛与卡托普利对轻度至中度原发性高血压合并血脂异常患者血脂浓度影响的双盲比较。

A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia.

作者信息

Hauf-Zachariou U, Widmann L, Zülsdorf B, Hennig M, Lang P D

机构信息

Department of Clinical Research, Boehringer Mannheim GmbH, Mannheim, Germany.

出版信息

Eur J Clin Pharmacol. 1993;45(2):95-100. doi: 10.1007/BF00315487.

DOI:10.1007/BF00315487
PMID:8223847
Abstract

We have studied 250 patients with mild to moderate essential hypertension (diastolic blood pressure 95-114 mmHg) and dyslipidaemia (high-density lipoprotein cholesterol (HDL-C) below 1.03 mmol.l-1, total cholesterol 5.17-9.05 mmol.l-1, and triglycerides 2.26-5.64 mmol.l-1) in a controlled double-blind, multicentre, parallel group trial. The patients took a fat-modified diet. After a 4-week placebo period, patients who continued to fulfil the selection criteria were randomly allocated to treatment with either carvedilol (a vasodilating beta-blocker) 25-50 mg o.d. (n = 116) or captopril (an ACE inhibitor) 25-50 mg o.d. (n = 117) for 6 months. In both groups there were favourable effects on the serum lipids. The relative changes (medians) in the carvedilol and captopril group were respectively: increase in HDL-C by 11% and 8%, decrease in total cholesterol by 11% and 10%, in low-density lipoprotein cholesterol by 16% and 12%, and in triglycerides by 13% and 14%. Equivalence of the two treatments was confirmed for the target variable change in HDL-C at a significance level of 5%. Reductions in supine systolic/diastolic blood pressures were comparable in the two groups (carvedilol: 23/19 mmHg, captopril: 20/18 mmHg). The improvement in lipid metabolism in patients treated with carvedilol is probably due to its alpha 1-blocking properties.

摘要

我们在一项对照双盲、多中心、平行组试验中研究了250例轻度至中度原发性高血压(舒张压95 - 114 mmHg)和血脂异常(高密度脂蛋白胆固醇(HDL - C)低于1.03 mmol·l⁻¹,总胆固醇5.17 - 9.05 mmol·l⁻¹,甘油三酯2.26 - 5.64 mmol·l⁻¹)的患者。患者采用低脂饮食。经过4周的安慰剂期后,继续符合入选标准的患者被随机分配接受卡维地洛(一种血管舒张性β受体阻滞剂)25 - 50 mg每日一次(n = 116)或卡托普利(一种ACE抑制剂)25 - 50 mg每日一次(n = 117)治疗6个月。两组对血脂均有有益作用。卡维地洛组和卡托普利组的相对变化(中位数)分别为:HDL - C升高11%和8%,总胆固醇降低11%和10%,低密度脂蛋白胆固醇降低16%和12%,甘油三酯降低13%和14%。在5%的显著性水平下,证实了两种治疗方法在HDL - C目标变量变化方面具有等效性。两组仰卧位收缩压/舒张压的降低程度相当(卡维地洛组:23/19 mmHg,卡托普利组:20/18 mmHg)。用卡维地洛治疗的患者脂质代谢的改善可能归因于其α1阻断特性。

相似文献

1
A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia.卡维地洛与卡托普利对轻度至中度原发性高血压合并血脂异常患者血脂浓度影响的双盲比较。
Eur J Clin Pharmacol. 1993;45(2):95-100. doi: 10.1007/BF00315487.
2
Effects of carvedilol on serum lipids in patients with essential hypertension.卡维地洛对原发性高血压患者血脂的影响。
J Cardiovasc Pharmacol. 1991;18 Suppl 4:S45-50.
3
Effects of carvedilol on serum lipids in hypertensive and normotensive subjects.卡维地洛对高血压和血压正常受试者血脂的影响。
Eur J Clin Pharmacol. 1990;38 Suppl 2:S139-42. doi: 10.1007/BF01409484.
4
Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients.卡维地洛与美托洛尔对糖尿病高血压患者血脂浓度的影响比较。
Diabetes Obes Metab. 2009 Mar;11(3):234-8. doi: 10.1111/j.1463-1326.2008.00927.x. Epub 2008 Jun 17.
5
Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial.卡维地洛和阿替洛尔对非胰岛素依赖型糖尿病和高血压患者的代谢及心血管影响:一项随机对照试验
Ann Intern Med. 1997 Jun 15;126(12):955-9. doi: 10.7326/0003-4819-126-12-199706150-00004.
6
Safety and antihypertensive efficacy of carvedilol and atenolol alone and in combination with hydrochlorothiazide.卡维地洛与阿替洛尔单用及与氢氯噻嗪联用的安全性和降压疗效。
Eur J Clin Pharmacol. 1990;38 Suppl 2:S143-6. doi: 10.1007/BF01409485.
7
Role of antioxidant property of carvedilol in mild to moderate hypertensive patients: A prospective open-label study.卡维地洛抗氧化特性在轻至中度高血压患者中的作用:一项前瞻性开放标签研究。
Indian J Pharmacol. 2016 Jul-Aug;48(4):372-376. doi: 10.4103/0253-7613.186206.
8
Long-term effects on plasma lipids of diet and drugs to treat hypertension. Treatment of Mild Hypertension Study (TOMHS) Research Group.饮食及药物治疗高血压对血脂的长期影响。轻度高血压治疗研究(TOMHS)研究组
JAMA. 1996;275(20):1549-56. doi: 10.1001/jama.1996.03530440029033.
9
Serum lipid levels in hypertensive patients during captopril treatment.卡托普利治疗期间高血压患者的血脂水平
Clin Ther. 1989 Nov-Dec;11(6):820-7.
10
Lipid profile and antihypertensive efficacy in hyperlipidemic hypertensive patients: comparison of rilmenidine and captopril.
J Cardiovasc Pharmacol. 1995;26 Suppl 2:S34-9.

引用本文的文献

1
Effects of Zofenopril on Arterial Stiffness in Hypertension Patients.佐芬普利对高血压患者动脉僵硬度的影响。
Mol Biotechnol. 2023 Sep 13. doi: 10.1007/s12033-023-00861-5.
2
Cytoprotective Potential of Aged Garlic Extract (AGE) and Its Active Constituent, S-allyl-l-cysteine, in Presence of Carvedilol during Isoproterenol-Induced Myocardial Disturbance and Metabolic Derangements in Rats.大蒜提取物(AGE)及其活性成分 S-烯丙基半胱氨酸在卡维地洛存在时对异丙肾上腺素诱导的大鼠心肌损伤和代谢紊乱的细胞保护作用。
Molecules. 2021 May 27;26(11):3203. doi: 10.3390/molecules26113203.
3
First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.

本文引用的文献

1
Study of seasonal variations for eighteen biochemical parameters over a four-year period.
Clin Biochem. 1982 Aug;15(4):206-11. doi: 10.1016/s0009-9120(82)90112-6.
2
Effects of antihypertensive therapy on plasma lipids and lipoproteins in the Multiple Risk Factor Intervention Trial.多重危险因素干预试验中降压治疗对血浆脂质和脂蛋白的影响。
Am J Med. 1984 Feb 27;76(2A):52-66. doi: 10.1016/0002-9343(84)90957-4.
3
The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering.脂质研究诊所冠心病一级预防试验结果。II. 冠心病发病率降低与胆固醇降低的关系。
用于治疗高血压的一线肾素-血管紧张素系统抑制剂与其他一线抗高血压药物类别对比
Cochrane Database Syst Rev. 2018 Nov 14;11(11):CD008170. doi: 10.1002/14651858.CD008170.pub3.
4
First-line renin-angiotensin system inhibitors vs. other first-line antihypertensive drug classes in hypertensive patients with type 2 diabetes mellitus.一线肾素-血管紧张素系统抑制剂与 2 型糖尿病高血压患者的其他一线降压药物类别相比。
J Hum Hypertens. 2018 Jul;32(7):494-506. doi: 10.1038/s41371-018-0066-x. Epub 2018 May 1.
5
Differential Metabolic Effects of Beta-Blockers: an Updated Systematic Review of Nebivolol.β受体阻滞剂的代谢差异效应:奈必洛尔的最新系统评价
Curr Hypertens Rep. 2017 Mar;19(3):22. doi: 10.1007/s11906-017-0716-3.
6
The effect of fat intake and antihypertensive drug therapy on serum lipid profile: a cross-sectional survey of serum lipids in male and female hypertensives.脂肪摄入量和抗高血压药物治疗对血清脂质谱的影响:男性和女性高血压患者血清脂质的横断面调查。
Mol Cell Biochem. 2010 Oct;343(1-2):37-47. doi: 10.1007/s11010-010-0496-4. Epub 2010 Jun 4.
7
Carvedilol modifies antioxidant status of patients with stable angina.卡维地洛可改善稳定型心绞痛患者的抗氧化状态。
Cell Mol Biol Lett. 2008;13(2):230-9. doi: 10.2478/s11658-007-0049-3. Epub 2008 Apr 10.
8
Metabolic properties of vasodilating beta blockers: management considerations for hypertensive diabetic patients and patients with the metabolic syndrome.血管舒张性β受体阻滞剂的代谢特性:高血压糖尿病患者及代谢综合征患者的管理考量
J Clin Hypertens (Greenwich). 2004 Dec;6(12):690-6; quiz 697. doi: 10.1111/j.1524-6175.2004.03704.x.
9
Beta blocker therapy after acute myocardial infarction in patients with heart failure and systolic dysfunction.心力衰竭合并收缩功能障碍患者急性心肌梗死后的β受体阻滞剂治疗
Heart Fail Rev. 2004 Apr;9(2):107-13. doi: 10.1023/B:HREV.0000046365.53467.f4.
10
Beta-blockers in the management of hypertension in patients with type 2 diabetes mellitus: is there a role?β受体阻滞剂在2型糖尿病患者高血压管理中的作用:是否有一席之地?
Drugs. 2001;61(4):429-35. doi: 10.2165/00003495-200161040-00001.
JAMA. 1984 Jan 20;251(3):365-74.
4
Influence of an angiotensin converting-enzyme inhibitor on diuretic-induced metabolic effects in hypertension.
Hypertension. 1983 Sep-Oct;5(5 Pt 2):III132-8. doi: 10.1161/01.hyp.5.5_pt_2.iii132.
5
Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.无需使用制备性超速离心机来估算血浆中低密度脂蛋白胆固醇的浓度。
Clin Chem. 1972 Jun;18(6):499-502.
6
Lipids and hypertension. Implications of new guidelines for cholesterol management in the treatment of hypertension.
Am J Med. 1986 Feb 14;80(2A):56-63. doi: 10.1016/0002-9343(86)90161-0.
7
Prevalence and prognostic significance of hypercholesterolemia in men with hypertension. Prospective data on the primary screenees of the Multiple Risk Factor Intervention Trial.高血压男性中高胆固醇血症的患病率及预后意义。多重危险因素干预试验初次筛查对象的前瞻性数据。
Am J Med. 1986 Feb 14;80(2A):33-9. doi: 10.1016/0002-9343(86)90158-0.
8
Cardiovascular morbidity in relation to change in blood pressure and serum cholesterol levels in treated hypertension. Results from the primary prevention trial in Göteborg, Sweden.
JAMA. 1987 Oct 2;258(13):1768-76.
9
Prazosin versus captopril as initial therapy. Effect on hypertension and lipid levels.
Am J Med. 1987 Jan 5;82(1A):58-63. doi: 10.1016/0002-9343(87)90146-x.
10
Effects of prazosin, atenolol, and thiazide diuretic on plasma lipids in patients with essential hypertension.哌唑嗪、阿替洛尔和噻嗪类利尿剂对原发性高血压患者血脂的影响。
Am J Med. 1986 Feb 14;80(2A):94-9. doi: 10.1016/0002-9343(86)90166-x.